Due to concerns over cost and participant risk, we did not collect tau PET data from our patient group, which could have provided novel information regarding the relationship between neurophysiological alterations and proteinopathy in Alzheimer’s disease. The gene discussed is MAPT; the disease is proteostasis deficiencies.